京新药业：公司JX2201美国暂未开展临床试验

Group 1 - The company JX2201 has entered Phase I clinical trials domestically and has received IND approval in the United States, raising questions about the potential for conducting clinical trials in the U.S. [1] - The company clarified that JX2201 has not yet commenced clinical trials in the U.S. and advised stakeholders to monitor relevant announcements for updates [1]